ABC:LSE-Abcam plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 1,142.00

Change

+22.00 (+1.96)%

Market Cap

GBX 2.36B

Volume

0.70M

Average Target Price

GBX 1,311.00 (+14.80%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GNS:LSE Genus plc

-8.00 (-0.25%)

GBX2.08B 55.52 55.37
PRTC:LSE PureTech Health plc

+20.00 (+9.30%)

GBX0.61B N/A -2.74
OXB:LSE Oxford BioMedica plc

-2.00 (-0.37%)

GBX0.41B N/A -240.81
SLN:LSE Silence Therapeutics plc

+29.00 (+5.97%)

GBX0.38B N/A -16.55
FARN:LSE Faron Pharmaceuticals Oy

+15.00 (+3.30%)

GBX0.20B N/A N/A
ERGO:LSE Ergomed plc

+15.00 (+3.85%)

GBX0.20B 35.22 17.63
BVXP:LSE Bioventix PLC

+515.00 (+15.99%)

GBX0.17B 28.72 22.95
DXRX:LSE Diaceutics PLC

+1.48 (+1.18%)

GBX0.09B 205.00 31.28
ARIX:LSE Arix Bioscience plc

-3.50 (-5.60%)

GBX0.08B N/A -0.43
CIR:LSE Circassia Pharmaceuticals plc

-0.10 (-0.59%)

GBX0.07B N/A -1.67

ETFs Containing ABC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.53% 64% D 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.53% 64% D 68% D+
Trailing 12 Months  
Capital Gain 0.62% 62% D- 80% B-
Dividend Return 0.76% 33% F 30% F
Total Return 1.37% 62% D- 79% C+
Trailing 5 Years  
Capital Gain 135.22% 89% B+ 95% A
Dividend Return 4.97% 33% F 36% F
Total Return 140.19% 85% B 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 23.72% 79% C+ 91% A-
Dividend Return 0.25% 25% F 32% F
Total Return 23.96% 79% C+ 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 19.33% 91% A- 45% F
Risk Adjusted Return 123.97% 98% A+ 97% A+
Market Capitalization 2.36B 100% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.38 71% C- 8% F
Price/Book Ratio 601.37 21% F 7% F
Price / Cash Flow Ratio 33.63 5% F 7% F
EV/EBITDA 28.42 11% F 6% F
Management Effectiveness  
Return on Equity 11.47% 95% A 68% D+
Return on Invested Capital 16.62% 91% A- 86% B
Return on Assets 7.91% 93% A 85% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 49% F 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector